AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19845414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions
Number of subjects: 0
Study 19845414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for symptomatic management (anxiety or insomnia)
Number of subjects: 0
Study 19845414 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 17203013 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg, oral) in pathological gamblers
Number of subjects: 38
Study 17203013 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (3 mg, oral) in non-gambler controls
Number of subjects: 38
Study 15008861 — intervention group
Group type: EXPERIMENTAL
Intervention: BBL + BTX-A
Number of subjects: 30
Study 15008861 — intervention group
Group type: COMPARATOR
Intervention: BBL alone
Number of subjects: 30
Study 11913308 — intervention group
Group type: EXPERIMENTAL
Intervention: Baking Soda Chewing Gum
Number of subjects: 85
Study 11913308 — intervention group
Group type: COMPARATOR
Intervention: Breath Mint Placebo
Number of subjects: 85
Study 9336527 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncemented total hip prostheses
Number of subjects: 226
Study 9336527 — intervention group
Group type: COMPARATOR
Intervention: Cemented total hip prostheses
Number of subjects: 226
Study 7950475 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3602942 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (3 g daily for one week)
Number of subjects: 6
Study 3602942 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg daily for one week)
Number of subjects: 6
Study 29233548 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual weight-based (AWB) chemotherapy dosing
Number of subjects: 615
Study 29233548 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight/normal weight BMI subgroup
Number of subjects: 615
Study 29233548 — intervention group
Group type: EXPERIMENTAL
Intervention: BSA 25th-50th percentile
Number of subjects: 615
Study 29233548 — intervention group
Group type: COMPARATOR
Intervention: BMI categories
Number of subjects: 615
Study 26899254 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical writing support
Number of subjects: 233
Study 26899254 — intervention group
Group type: COMPARATOR
Intervention: No medical writing support
Number of subjects: 233
Study 24279429 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience (writing about death)
Number of subjects: 0
Study 24279429 — intervention group
Group type: COMPARATOR
Intervention: Aversive control topic (writing about a non-death topic)
Number of subjects: 0
Study 22554311 — intervention group
Group type: EXPERIMENTAL
Intervention: Fomepizole IV or orally (7 mg/kg)
Number of subjects: 0
Study 22554311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loading doses of 10‐15 mg/kg, followed by supplemental doses of 3‐10 mg/kg/12 h through 96 hours
Number of subjects: 0
Study 20861293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg at night
Number of subjects: 51
Study 20861293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 17588821 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-1 Putty
Number of subjects: 36
Study 17588821 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft
Number of subjects: 36
Study 16000995 — intervention group
Group type: COMPARATOR
Intervention: International guidelines single-sample estimates of GFR
Number of subjects: 425
Study 16000995 — intervention group
Group type: EXPERIMENTAL
Intervention: New equation derived from the data
Number of subjects: 425
Study 16000995 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope-intercept method described in the BNMS guidelines
Number of subjects: 425
Study 14597346 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU followed by mastectomy
Number of subjects: 48
Study 14597346 — intervention group
Group type: COMPARATOR
Intervention: Control group (mastectomy)
Number of subjects: 48
Study 12851773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine extended-release 4 mg once daily
Number of subjects: 410
Study 10425569 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease activity index
Number of subjects: 110
Study 10425569 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory variables (erythrocyte sedimentation rate, chloraemia, serum albumin)
Number of subjects: 110
Study 7781461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 276
Study 7781461 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 276
Study 2114429 — intervention group
Group type: EXPERIMENTAL
Intervention: Orem's Self-Care Deficit Nursing Theory
Number of subjects: 0
Study 2114429 — intervention group
Group type: COMPARATOR
Intervention: Control unit (standard nursing care)
Number of subjects: 0
Study 362518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbenicillin
Number of subjects: 16
Study 362518 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 16
Study 31590569 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walk test
Number of subjects: 60
Study 31590569 — intervention group
Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 60
Study 27999024 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam
Number of subjects: 94
Study 27999024 — intervention group
Group type: COMPARATOR
Intervention: meropenem
Number of subjects: 94
Study 27999024 — intervention group
Group type: COMPARATOR
Intervention: levofloxacin
Number of subjects: 94
Study 25297064 — intervention group
Group type: EXPERIMENTAL
Intervention: EF (3.0 g/L oligofructose)
Number of subjects: 95
Study 25297064 — intervention group
Group type: COMPARATOR
Intervention: CF (α-lactalbumin-enriched control formula)
Number of subjects: 95
Study 23360899 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 vol.% nitrous oxide (N2O)
Number of subjects: 0
Study 23360899 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 21288228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil bolus (0.4 μg/kg) administered immediately after a contraction trigger
Number of subjects: 50
Study 21288228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil bolus (0.4 μg/kg) administered 140 seconds before the next contraction
Number of subjects: 50
Study 21288228 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed boluses in a subgroup with long and regular contractions
Number of subjects: 50
Study 21288228 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 50
Study 19262478 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren alone or in combination with a diuretic or a calcium channel blocker (CCB)
Number of subjects: 345
Study 16902750 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training
Number of subjects: 0
Study 16902750 — intervention group
Group type: COMPARATOR
Intervention: Mechanical robotic training
Number of subjects: 0
Study 15692716 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial carbon dioxide rebreathing
Number of subjects: 20
Study 15692716 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution
Number of subjects: 20
Study 11709518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg four times daily)
Number of subjects: 28
Study 11709518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9358913 — intervention group
Group type: EXPERIMENTAL
Intervention: Asbestos-exposed individuals
Number of subjects: 292
Study 9358913 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed heavy smokers
Number of subjects: 292
Study 7962879 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-effects regression model for clustered data
Number of subjects: 0
Study 7962879 — intervention group
Group type: COMPARATOR
Intervention: Ordinary regression analysis of clustered data
Number of subjects: 0
Study 7962879 — intervention group
Group type: COMPARATOR
Intervention: Classroom-level analysis
Number of subjects: 0
Study 3668983 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1.5 mg daily
Number of subjects: 15
Study 3668983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31524498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily
Number of subjects: 263
Study 31524498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 27902645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Stimulation (NS)
Number of subjects: 80
Study 27902645 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US)
Number of subjects: 80
Study 25376434 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscular training (IMT)
Number of subjects: 44
Study 25376434 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 44
Study 23480238 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk (PFM) containing Bifidobacterium lactis CNCM I-2494
Number of subjects: 324
Study 23480238 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk (PFM)
Number of subjects: 324
Study 23480238 — intervention group
Group type: COMPARATOR
Intervention: Control dairy product
Number of subjects: 324
Study 21664867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab (10 mg/kg every 2 weeks) and temsirolimus (25 mg weekly; group A)
Number of subjects: 171
Study 21664867 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg/day for 4 weeks followed by 2 weeks off; group B)
Number of subjects: 171
Study 21664867 — intervention group
Group type: COMPARATOR
Intervention: Combination of interferon alfa (9 mIU three times per week) and bevacizumab (10 mg/kg every 2 weeks; group C)
Number of subjects: 171
Study 21664867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab and temsirolimus (group A)
Number of subjects: 171
Study 21664867 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (group B)
Number of subjects: 171
Study 21664867 — intervention group
Group type: COMPARATOR
Intervention: Combination of interferon alfa and bevacizumab (group C)
Number of subjects: 171
Study 19835123 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory-needling method (INM)
Number of subjects: 80
Study 19835123 — intervention group
Group type: COMPARATOR
Intervention: Routine-needling method (RNM)
Number of subjects: 80
Study 19835123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 17537152 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg day(-1))
Number of subjects: 18
Study 17537152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14982784 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir every 8 h (n = 8)
Number of subjects: 25
Study 14982784 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 1000 mg every 12 h with nelfinavir (n = 10)
Number of subjects: 25
Study 14982784 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 1200 mg every 12 h with nelfinavir (n = 7)
Number of subjects: 25
Study 14982784 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir with nelfinavir (combined data)
Number of subjects: 25
Study 14982784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (in combination with indinavir 1000 mg every 12 h) (n = 9)
Number of subjects: 25
Study 11133744 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal ATRA (90 mg/m(2) every other day until complete remission or a maximum of 56 days)
Number of subjects: 69
Study 11133744 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal ATRA
Number of subjects: 69
Study 9468068 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated alteplase
Number of subjects: 40747
Study 9468068 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase or combination therapy
Number of subjects: 40747
Study 9468068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prior myocardial infarction
Number of subjects: 40747
Study 9468068 — intervention group
Group type: COMPARATOR
Intervention: Patients without prior myocardial infarction
Number of subjects: 40747
Study 7865956 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc extended radical mastectomy (EXT)
Number of subjects: 118
Study 7865956 — intervention group
Group type: COMPARATOR
Intervention: Conventional radical mastectomy (RDL)
Number of subjects: 118
Study 2464777 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 60
Study 2464777 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 60
Study 773601 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacycline 600 mg daily for 14 days
Number of subjects: 20
Study 773601 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 2 gm daily for 14 days
Number of subjects: 20
Study 31764258 — intervention group
Group type: COMPARATOR
Intervention: Placebo products (crossover study)
Number of subjects: 0
Study 31764258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets, ring, and injections (TRIO study)
Number of subjects: 0
Study 31764258 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal products (ring, insert, film, and gel) (Quatro study)
Number of subjects: 0
Study 31764258 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete choice experiment
Number of subjects: 0
Study 27319277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 102
Study 27319277 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 102
Study 27319277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and intravenous ibuprofen
Number of subjects: 102
Study 25222105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive low‐GL intervention
Number of subjects: 95
Study 25222105 — intervention group
Group type: COMPARATOR
Intervention: General dietary intervention (Control group)
Number of subjects: 95
Study 24338756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap Assisted Colonoscopy (CAC)
Number of subjects: 504
Study 24338756 — intervention group
Group type: COMPARATOR
Intervention: Conventional Colonoscopy (CC)
Number of subjects: 504
Study 22052276 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using 20% 5‐aminolevulinic acid solution (ALA) and blue light
Number of subjects: 15
Study 22052276 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA with blue light
Number of subjects: 15
Study 22052276 — intervention group
Group type: COMPARATOR
Intervention: ALA vehicle and blue light
Number of subjects: 15
Study 22052276 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using ALA with blue light
Number of subjects: 15
Study 18632591 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated eGFR reporting and clinician education
Number of subjects: 1019
Study 17215967 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Number of subjects: 93
Study 17215967 — intervention group
Group type: COMPARATOR
Intervention: Glucometer-guided insulin injection
Number of subjects: 93
Study 12966017 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling and a safety kit including preventive devices and pamphlets about indoor injuries (Group 1)
Number of subjects: 100
Study 12966017 — intervention group
Group type: COMPARATOR
Intervention: Counselling only (Group 2)
Number of subjects: 100
Study 10849057 — intervention group
Group type: EXPERIMENTAL
Intervention: RACM regimen (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid, metronidazole 250 mg bid)
Number of subjects: 105
Study 10849057 — intervention group
Group type: COMPARATOR
Intervention: RAC regimen (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid)
Number of subjects: 105
Study 10849057 — intervention group
Group type: EXPERIMENTAL
Intervention: RACM regimen
Number of subjects: 105
Study 10849057 — intervention group
Group type: COMPARATOR
Intervention: RAC regimen
Number of subjects: 105
Study 9107431 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of oltipraz daily
Number of subjects: 234
Study 9107431 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of oltipraz weekly
Number of subjects: 234
Study 9107431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1153
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 1153
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both radiotherapy and cyclophosphamide
Number of subjects: 1153
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1153
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both radiotherapy and tamoxifen
Number of subjects: 1153
Study 8260183 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 1153
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment only
Number of subjects: 1153
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgery, radiotherapy and hormone therapy
Number of subjects: 1153
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 1153
Study 8260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive local treatment with hormone therapy
Number of subjects: 1153
Study 3535975 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine
Number of subjects: 0
Study 3535975 — intervention group
Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 0
Study 30845920 — intervention group
Group type: EXPERIMENTAL
Intervention: CELC (vitamin C, vitamin E, lysozyme, and carbazochrome)
Number of subjects: 100
Study 30845920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29397594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group C (live combined Bacillus subtilis and Enterococcus)
Number of subjects: 200
Study 29397594 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment with polyene phosphatidylcholine capsules)
Number of subjects: 200
Study 29397594 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 200
Study 29397594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (A, B, C)
Number of subjects: 200
Study 27509606 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 27509606 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of lipoic acid (0.6 g) and alprostadil (10 mg)
Number of subjects: 60
Study 25392671 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic pyeloplasty
Number of subjects: 112
Study 25392671 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneoscopic laparoscopic pyeloplasty
Number of subjects: 112
Study 22889884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast IOL insertion (1 revolution per second)
Number of subjects: 80
Study 22889884 — intervention group
Group type: COMPARATOR
Intervention: Slow IOL insertion (¼ revolution per second)
Number of subjects: 80
Study 22889884 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group F)
Number of subjects: 80
Study 22889884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 20093960 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weight bench press at 70% 1RM
Number of subjects: 0
Study 20093960 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weight bench press at 90% 1RM
Number of subjects: 0
Study 20093960 — intervention group
Group type: COMPARATOR
Intervention: Smith machine bench press at 70% 1RM
Number of subjects: 0
Study 20093960 — intervention group
Group type: COMPARATOR
Intervention: Smith machine bench press at 90% 1RM
Number of subjects: 0
Study 17106431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze Stabilization Test (GST)
Number of subjects: 14
Study 17106431 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 14
Study 17106431 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unilateral vestibular dysfunction
Number of subjects: 14
Study 15111228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop signal task combined with flanker task
Number of subjects: 0
Study 15111228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop signal task combined with manual version of the Stroop task
Number of subjects: 0
Study 11572296 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomers
Number of subjects: 80
Study 11572296 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin-based composites
Number of subjects: 80
Study 11572296 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomers
Number of subjects: 80
Study 11572296 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 additional teeth)
Number of subjects: 80
Study 10321449 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (antihypertensive doses)
Number of subjects: 0
Study 10321449 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (non-antihypertensive doses)
Number of subjects: 0
Study 10321449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathicolytic agents
Number of subjects: 0
Study 7933259 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat percutaneous transluminal angioplasty (rPTA)
Number of subjects: 93
Study 7933259 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial bypass
Number of subjects: 93
Study 7933259 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive therapy (exercise and medication)
Number of subjects: 93
Study 3202402 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 30 mg/kg per dose, 4 doses every 6 hours
Number of subjects: 87
Study 3202402 — intervention group
Group type: COMPARATOR
Intervention: Mannitol placebo
Number of subjects: 87
Study 3202402 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 87
Study 30132011 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with a behavioural approach
Number of subjects: 165